MktsMarkets

Avalo Therapeutics, Inc.
NASDAQ: AVTXKey statistics
AVTX News
Stories mentioning AVTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 192.00 | 249.00 | 0.00 | ||||
| Cost of Goods Sold | 0.00 | (714.00) | 343.00 | |||||
| Gross Profit | 0.00 | 0.00 | 0.00 | (343.00) | ||||
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (20,901) | (19,742) | (19,198) | (19,316) | (14,669) | (13,309) | (12,861) | (9,575) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (3.00) | (5.00) | 0.00 | (5.00) | 0.00 | |||
| Pretax Income | (19,618) | (13,590) | (30,614) | (20,749) | (13,141) | (35,225) | 23,023 | 98,470 |
| Tax Provision | 12.00 | 130.00 | 11.00 | 16.00 | 8.00 | 114.00 | (14.00) | 7.00 |
| Net Income (Loss) | (19,630) | (13,720) | (30,625) | (20,765) | (13,149) | (35,339) | 23,037 | 98,463 |
| Earnings Per Share (Basic) | (0.98) | (1.02) | (2.19) | (1.92) | (1.25) | (7.98) | 0.98 | 4.21 |
| Earnings Per Share (Diluted) | (0.98) | (1.02) | (2.19) | (1.92) | (1.25) | (4.71) | (2.83) | (14.07) |
| Weighted Average Shares Outstanding (Basic) | 20,107 | 13,405 | 14,000 | 10,830 | 10,515 | 4,426 | 5,546 | 1,034 |
| Weighted Average Shares Outstanding (Diluted) | 20,107 | 13,405 | 14,000 | 10,830 | 10,515 | 7,496 | 10,784 | 7,653 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About AVTX
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol AVTX. It last traded at $7.17 (Oct 30, 2026, 4:00 PM ET), down 3.6% on the day. That gives Avalo Therapeutics a market capitalisation of $384.5M.
Over the past 52 weeks AVTX has traded between $6.53 and $24.27.
For the quarter ended Mar 31, 2026 it reported a net loss of $19.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$19.6M |
| Dec 31, 2025 | — | -$13.7M |
| Sep 30, 2025 | $0 | -$30.6M |
| Jun 30, 2025 | — | -$20.8M |
From Avalo Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…